Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails

by Zacks Equity Research

Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.

    Zacks Equity Research

    Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

    by Zacks Equity Research

    Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

      Zacks Equity Research

      Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates

      by Zacks Equity Research

      Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.

        Zacks Equity Research

        Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)

        by Zacks Equity Research

        Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

          Zacks Equity Research

          Align Technology International Growth Solid, Rivalry Rife

          by Zacks Equity Research

          Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.

            Zacks Equity Research

            Why You Should Add Chemed (CHE) Stock to Your Portfolio Now

            by Zacks Equity Research

            Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.

              Zacks Equity Research

              Here's Why You Should Invest in Illumina (ILMN) Stock Now

              by Zacks Equity Research

              Illumina (ILMN) gains on strategic partnerships and international prospects.

                Zacks Equity Research

                Ecolab's New Aquanomic Enhances Laundry Operations at Hotels

                by Zacks Equity Research

                Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.

                  Zacks Equity Research

                  Cerner (CERN) Strong on EHR Prospects, Competition Intense

                  by Zacks Equity Research

                  Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.

                    Zacks Equity Research

                    Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

                    by Zacks Equity Research

                    Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

                      Zacks Equity Research

                      DaVita Healthcare Partners' New Facility Now in Los Angeles

                      by Zacks Equity Research

                      DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.

                        Zacks Equity Research

                        Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now

                        by Zacks Equity Research

                        Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                          Zacks Equity Research

                          Masimo (MASI) Scales a 52-Week High: What's Driving It?

                          by Zacks Equity Research

                          Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

                            Zacks Equity Research

                            Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

                            by Zacks Equity Research

                            Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

                              Zacks Equity Research

                              Avanos Medical (AVNS) Jumps: Stock Rises 5.5%

                              by Zacks Equity Research

                              Avanos Medical (AVNS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

                                Zacks Equity Research

                                Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines

                                by Zacks Equity Research

                                All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.

                                  Zacks Equity Research

                                  Is Integer Holdings (ITGR) Stock Outpacing Its Medical Peers This Year?

                                  by Zacks Equity Research

                                  Is (ITGR) Outperforming Other Medical Stocks This Year?

                                    Zacks Equity Research

                                    Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                                    by Zacks Equity Research

                                    Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.

                                      Zacks Equity Research

                                      Becton, Dickinson Hits at a 52-Week High: What's Driving It?

                                      by Zacks Equity Research

                                      Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.

                                        Zacks Equity Research

                                        Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y

                                        by Zacks Equity Research

                                        Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.

                                          Zacks Equity Research

                                          Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

                                          by Zacks Equity Research

                                          Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.

                                            Zacks Equity Research

                                            CVS Health's PBM Selling Season Strong, Aetna Deal on Track

                                            by Zacks Equity Research

                                            A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.

                                              Zacks Equity Research

                                              Amedisys (AMED) Grows on Robust Home Health, Personal Care

                                              by Zacks Equity Research

                                              Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.

                                                Zacks Equity Research

                                                ITGR or LMNX: Which Is the Better Value Stock Right Now?

                                                by Zacks Equity Research

                                                ITGR vs. LMNX: Which Stock Is the Better Value Option?

                                                  Zacks Equity Research

                                                  Integra LifeSciences Codman Arm Strong, Competition Rife

                                                  by Zacks Equity Research

                                                  Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.